If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
218
results.
Updated on
23/12/2025 [06:52:00]
Results 125 to 150 of 218
Absstract of: CN121108003A
本申请公开了一种免疫细胞靶向的脂质纳米颗粒及其筛选方法和用途，具体公开了式(I)的化合物或其药学上可接受的盐、前药或立体异构体在靶向免疫细胞中的用途，LNP‑mRNA复合物递送线性mRNA和环状mRNA可在体内稳定表达，且可以同时编辑多种免疫细胞，在肺转移模型和实体瘤模型中治疗效果显著；同时公开一种体外筛选脂质纳米颗粒的方法和一种筛选适用于体内多种免疫细胞mRNA递送的脂质纳米粒颗粒的方法，解决了直接在原代巨噬细胞筛选导致的原代细胞用量高、提取原代细胞时间长的问题。
Absstract of: CN121102267A
本发明公开了一种抗炎的多糖类口腔抑菌组合物及其制备工艺，属于生物医学材料技术领域。该制备工艺包括如下步骤：将壳聚糖溶解于乙酸水溶液中，搅拌处理得到预配溶液；配制三聚磷酸钠水溶液，匀速滴加壳聚糖溶液，混匀得到纳米核悬浮液；将表没食子儿茶素没食子酸酯溶于缓冲液，加入纳米核悬浮液孵育，离心回收得到多酚负载颗粒；加入透明质酸钠溶液，静置获得核壳纳米颗粒；与锌离子溶液共混混合；加入木糖醇与枸橼酸/枸橼酸钠缓冲盐，除菌过滤；喷雾干燥得到粉末剂型。该组合物具有优异的抑菌率、抗炎效能、稳定性和生物相容性，适用于口腔护理产品。
Absstract of: CN121109385A
本申请提供一种靶向中枢神经系统促进瘦素敏感性的工程化外泌体及其制备方法和应用，具体提供抑制脂肪合成的RNAi、靶向中枢神经系统促进瘦素敏感性的工程化外泌体、及其制备方法和在制备肥胖治疗的药物中的应用。本申请制备的工程化外泌体具有SIRPα和MCAM蛋白，可以高效靶向中枢神经系统，同时外泌体表面上有靶向瘦素受体神经元的靶向肽和瘦素片段的LEP(61‑90)‑Lam2b融合蛋白，最终使得外泌体高效靶向中枢神经系统后，与瘦素受体神经元结合；外泌体装载的具有瘦素增敏作用的miRNAs可显著提高中枢瘦素敏感性，发挥减重作用。
Absstract of: US2025375393A1
A method for preparing protein-based nanoparticle for self-packaging and delivering mRNA includes the following steps. A first donor plasmid, a second donor plasmid and a third donor plasmid are provided. A plasmid transposing step is performed. A recombinant virus preparing step is performed so as to obtain a first recombinant baculovirus, a second recombinant baculovirus and a third recombinant baculovirus. A transducing step is performed, wherein the first recombinant baculovirus, the second recombinant baculovirus and the third recombinant baculovirus are used to infect a producer cell so as to express a nucleocapsid protein, an envelope protein, an engineered envelope protein and a target RNA, and the nucleocapsid protein, the envelope protein, the engineered envelope protein and the target RNA are self-assembled to form a protein-based nanoparticle for self-packaging and delivering mRNA.
Absstract of: WO2025251157A1
Provided herein is a method of treating or preventing or diagnosing a central nervous system central nervous system disease, disorder, trauma or injury. The method comprises use of a lipid nanoparticle comprising at least one nucleic acid encoding an antibody or antigen-binding fragment and the lysosomal enzyme glucocerebrosidase. Also provided is a lipid nanoparticle that can be used with the method disclosed herein.
Absstract of: US2025375534A1
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or a cationic polymer, wherein nucleic acid particles described herein reduce inflammatory response and/or increase protein or antigen expression associated with previous formulations.
Absstract of: US2025375532A1
The present disclosure described bi-functional delivery particles with the ability to bind to two different cell types in a distinct fashion. Employing a first ligand with differential binding capabilities, the delivery particles may bind to a first target, such as cell, in a reversible fashion such that when they encounter a second target (e.g., cell) a second ligand that bind irreversibly to the second target will disrupt the binding to the first target. As such, the first target acts as a carrier to delivery the particle to a diagnostic or therapeutic second target. In particular aspects, the first and second cells are circulating cells.
Absstract of: US2025375537A1
Methods and compositions for genetically modifying a cell are provided.
Absstract of: US2025375392A1
Ionizable lipids having branched tails, nanoparticles containing the ionizable lipids, compositions containing the nanoparticles, and methods for using the ionizable lipids, nanoparticles, and compositions to deliver agents (e.g., RNAs) to cells, tissues, and/or organs are provided herein.
Absstract of: US2025375378A1
Composition and methods for treating Niemann-Pick disease type C are disclosed, utilizing lipid nanoparticles (LNPs) encapsulating mRNA sequences coding for NPC1 and/or NPC2 proteins.
Absstract of: US2025375389A1
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Absstract of: US2025375377A1
An opioid independent surgical anesthetic composition includes an injectable dosage form of a hydrogel having a plurality of solid lipid matrix particles entrapped therein. The solid lipid matrix particles include a lipophilic local anesthetic drug and a lipid glyceride (e.g., saturated triglyceride or lipid blend of various lipid glycerides). Methods for creating a long-acting local anesthetic product can include creating a bulk solid of a lipid matrix product by heating a lipid solvent above its melting point, dissolving a lipophilic local anesthetic drug therein, reducing a temperature of the resultant drug-lipid solution to below the melting point of the lipid solvent, and heat annealing the lipid matrix to remove or reduce presence of any unstable polymorphs in the lipid matrix. The methods can further include crushing the bulk solid of the lipid matrix product to form solid lipid matrix particles and entrapping the solid lipid matrix particles within a hydrogel.
Absstract of: US2025375391A1
The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.
Absstract of: US2025376534A1
Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
Absstract of: US2025375386A1
Provided herein are achromosomal dynamic active systems comprising a Type 1 pilus (TIP) and methods of making and using the same.
Absstract of: US2025375388A1
The present invention relates to nanoparticles associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) associated with (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).
Absstract of: US2025375387A1
The present disclosure relates to nanoparticles containing cellular membrane and uses thereof. The nanoparticle comprises an interior compartment (or an inner core) and an outer surface (or shell) comprising a cellular membrane derived from a cell, said interior compartment (or an inner core) not providing a solid support to said cellular membrane in said outer surface (or shell). The present disclosure also relates to processes of making the nanoparticles. The present disclosure further relates to compositions comprising the nanoparticles and methods of using the nanoparticles.
Absstract of: US2025375390A1
The present invention provides lyophilised pharmaceutical compositions and methods of making said lyophilised pharmaceutical compositions. More particularly, the present invention provides lyophilised pharmaceutical compositions comprising nucleic acid and lipid carrier particles and methods of making said lyophilised pharmaceutical compositions. The provided lyophilised compositions have improved critical quality attributes (CQAs) and the provided methods prevent the need for a deep-freeze cold chain. The present invention further provides the use of said lyophilised pharmaceutical compositions in medicine.
Absstract of: US2025376686A1
A multi-functional near-infrared fluorescent polymer dot (Pdot)-siRNA nanoplatform is disclosed herein. The disclosed technology addresses challenges in siRNA delivery, including poor stability, degradation, and immune recognition, by utilizing positively charged Pdots synthesized from polymers, and electrostatic binding with negatively charged siRNA. The Pdots exhibit dual fluorescence emission at 588 nm and 775 nm, enabling real-time visualization of cellular uptake and siRNA delivery. The nanoplatform demonstrates efficient inhibition of target gene expression, and protein levels in cells. The Pdots provide minimal toxicity and persist in cells for extended periods, offering a robust tool for therapeutic applications, bioimaging, and molecular labeling. This approach combines siRNA delivery with simultaneous imaging, presenting a versatile method for targeted gene regulation and research applications.
Absstract of: KR20250173666A
본 발명은 핵산 전달체에 관한 것으로서, 보다 상세하게는 다수의 핵산을 포함하는 핵산 코어 및 상기 핵산 코어의 표면을 코팅하는 지질 코팅층을 포함하고, 상기 지질 코팅층은 양이온성 지질, 중성 지질 및 PEG화 지질을 포함하는 핵산 코팅용 지질 조성물을 포함함으로써 상기 핵산을 세포에 전달할 때의 독성을 최소화할 수 있는 핵산 전달체에 관한 것이다.
Absstract of: US2024122864A1
The present invention provides compositions comprising biodegradable particles that encapsulate two or more epitopes linked together by one or more linkers that are susceptible to cleavage by specific proteases. The present invention further provides methods for inducing antigen-specific tolerance and protective immune responses and for the treatment inflammatory diseases, such as autoimmune diseases, allergies, cancers, or infectious diseases.
Absstract of: US2025361208A1
Provided herein are lipids having the Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Absstract of: JP2025028132A
To provide prostacyclin compounds and compositions comprising the same.SOLUTION: Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.SELECTED DRAWING: None
Absstract of: JP2024009057A
To satisfy a need to develop novel means of extracting metals from the body, with the aim of preventing and/or treating pathologies related to dysregulation of metal homeostasis.SOLUTION: The present invention relates to the field of medical devices, more particularly to devices for extracting metals from an organism. The use of these devices makes it possible, for example, to prevent and/or treat pathologies linked to dysregulation of metal homeostasis in the organism, for example neurological diseases.SELECTED DRAWING: Figure 1
Nº publicación: JP2025540076A 11/12/2025
Applicant:
ジェネレーションバイオカンパニー
Absstract of: CN120641085A
Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA) wherein the LNP comprises an ionizable lipid; a "helper" lipid, such as ceramide or distearoyl phosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid anchoring polymers; and uses thereof.
BOPI
Electronic site
